30 closest matches · ranked by relevance
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
Breast Cancer
Primary: Success Rate — 65.4 percentage of participants
Radiation Toxicity
Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5
Breast Cancer
Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077
Coronary Artery Disease · Chest Pain
Primary: Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging — 0.183; 0.159 gamma-H2AX foci in blood lymphocytes — p=<0.05
Low Grade Gliomas
Primary: Number of Participants With Late Effects > 3 Months Post RT — 20 Participants
Radiation Toxicity · Recurrent Breast Cancer · Stage I Breast Cancer
Primary: Acute and Grade 2 or Higher Radiation-related Skin Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 38; 38 percentage of…
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Breast Cancer
Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins
Cancer, Breast · Inflammation
Primary: Number of Participants Per Cutaneous Toxicity Grade (0, 1, 2, 3, 4) — 60; 11; 0; 0 Participants
Head and Neck Neoplasms
Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants
Radiodermatitis · Injury, Radiation
Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants
Breast Cancer
Primary: The Number of Participants With a Significant Increase in Perfusion Defects (PD) — 1; 2; 3; 5 participants — p=0.6
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Radiodermatitis · Quality of Life
Primary: Proportion of Patients Without Grade G2 Skin Toxicity Radiodermatitis at Week 5 — 10; 5; 13; 11 participants
Malignant Bone Tumors
Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
Radiation Dermatitis
Primary: Grade 3 or Higher Adverse Events — 9 Participants
Prostatic Neoplasms
Primary: Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With…
Prostate Cancer
Primary: Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity — 20 participants
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Hepatocellular Carcinoma
Primary: The Proportion of Patients for Whom the Intended Treatment Was Feasible — 70 Participants
Synovial Sarcoma · Single or Multiple Lung Metastases
Primary: Number of Participants Evaluated for Toxicity — 10 Participants
Metastatic Melanoma
Primary: Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Radiodermatitis · Dermatitis, Radiation-Induced
Primary: Number of Participants With Progression of Radio Therapy Induced Skin Reaction — 35; 33 Participants
Breast Cancer
Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
Prostate Cancer
Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events
Non-rhabdomyosarcoma Soft Tissue Sarcoma · Bone Sarcoma
Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants
Breast Cancer
Primary: Local Recurrence Rate — 0 Participants